{"organizations": [], "uuid": "9b56e1fcbe80b9d88285c861f0da18664a06be32", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180115.html", "section_title": "Archive News &amp; Video for Monday, 15 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-teva-announces-fda-approval-of-tri/brief-teva-announces-fda-approval-of-trisenox-to-treat-acute-promyelocytic-leukemia-idUSASB0C0WK", "country": "US", "domain_rank": 408, "title": "BRIEF-Teva Announces FDA Approval Of Trisenox To Treat Acute Promyelocytic Leukemia", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-15T21:24:00.000+02:00", "replies_count": 0, "uuid": "9b56e1fcbe80b9d88285c861f0da18664a06be32"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-teva-announces-fda-approval-of-tri/brief-teva-announces-fda-approval-of-trisenox-to-treat-acute-promyelocytic-leukemia-idUSASB0C0WK", "ord_in_thread": 0, "title": "BRIEF-Teva Announces FDA Approval Of Trisenox To Treat Acute Promyelocytic Leukemia", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "teva", "sentiment": "negative"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 15 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* TEVA ANNOUNCES U.S. FDA APPROVAL OF TRISENOX® (ARSENIC TRIOXIDE) INJECTION FOR FIRST LINE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA\n* TEVA PHARMACEUTICAL-‍APPROVAL BASED ON REVIEW BY FDA ON DATA FROM PUBLISHED SCIENTIFIC LITERATURE AND CO‘S GLOBAL SAFETY DATABASE FOR ARSENIC TRIOXIDE​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-15T21:24:00.000+02:00", "crawled": "2018-01-16T13:12:34.000+02:00", "highlightTitle": ""}